KR20070090004A - 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법 - Google Patents

4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법 Download PDF

Info

Publication number
KR20070090004A
KR20070090004A KR1020077015972A KR20077015972A KR20070090004A KR 20070090004 A KR20070090004 A KR 20070090004A KR 1020077015972 A KR1020077015972 A KR 1020077015972A KR 20077015972 A KR20077015972 A KR 20077015972A KR 20070090004 A KR20070090004 A KR 20070090004A
Authority
KR
South Korea
Prior art keywords
formula
azd0530
compound
salt
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077015972A
Other languages
English (en)
Korean (ko)
Inventor
제임스 가이어 포드
제임스 프란시스 맥케이브
앤 오키어니-맥뮬란
필립 오키페
시몬 마크 포인톤
린 포웰
마크 퍼디
제인 위드날
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20070090004A publication Critical patent/KR20070090004A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020077015972A 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법 Ceased KR20070090004A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0427697.8A GB0427697D0 (en) 2004-12-17 2004-12-17 Chemical process
GB0427697.8 2004-12-17

Related Child Applications (5)

Application Number Title Priority Date Filing Date
KR1020087023969A Division KR20080094846A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020117022793A Division KR20110114727A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020087023973A Division KR20080094849A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020087023971A Division KR20080094847A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020087023972A Division KR20080094848A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법

Publications (1)

Publication Number Publication Date
KR20070090004A true KR20070090004A (ko) 2007-09-04

Family

ID=34090249

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020077015972A Ceased KR20070090004A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020087023973A Withdrawn KR20080094849A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020087023969A Withdrawn KR20080094846A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020087023972A Withdrawn KR20080094848A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020087023971A Withdrawn KR20080094847A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020117022793A Ceased KR20110114727A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법

Family Applications After (5)

Application Number Title Priority Date Filing Date
KR1020087023973A Withdrawn KR20080094849A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020087023969A Withdrawn KR20080094846A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020087023972A Withdrawn KR20080094848A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020087023971A Withdrawn KR20080094847A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법
KR1020117022793A Ceased KR20110114727A (ko) 2004-12-17 2005-12-14 4-(6-클로로-2,3-메틸렌다이옥시아닐리노)-7-[2-(4-메틸피페라진-1-일)에톡시]-5-테트라하이드로피란-4-일옥시퀴나졸린, 이의 중간체 및 이의 결정질 염의 제조 방법

Country Status (16)

Country Link
US (1) US8304417B2 (cg-RX-API-DMAC7.html)
EP (1) EP1871769B1 (cg-RX-API-DMAC7.html)
JP (2) JP5161584B2 (cg-RX-API-DMAC7.html)
KR (6) KR20070090004A (cg-RX-API-DMAC7.html)
CN (1) CN101115744B (cg-RX-API-DMAC7.html)
AU (2) AU2005315458B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519085A2 (cg-RX-API-DMAC7.html)
CA (2) CA2590735C (cg-RX-API-DMAC7.html)
ES (1) ES2622480T3 (cg-RX-API-DMAC7.html)
GB (1) GB0427697D0 (cg-RX-API-DMAC7.html)
IL (1) IL183525A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007007210A (cg-RX-API-DMAC7.html)
NO (1) NO20072755L (cg-RX-API-DMAC7.html)
NZ (1) NZ555468A (cg-RX-API-DMAC7.html)
WO (1) WO2006064217A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200704532B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
CN103275072B (zh) * 2013-05-22 2016-01-20 苏州明锐医药科技有限公司 塞卡替尼的制备方法
US10660957B2 (en) * 2013-06-13 2020-05-26 Yale University Compositions and methods for treating an Aβ-modulated disease or disorder or improving cognition in a subject
US11241434B2 (en) 2013-06-13 2022-02-08 Yale Uninversity Compositions and methods for improving cognition in a subject
WO2016130897A1 (en) 2015-02-13 2016-08-18 Yu Paul B Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
FI3930715T3 (fi) 2019-02-27 2024-08-05 Astrazeneca Ab Sarakatinibi käytettäväksi idiopaattisen keuhkofibroosin hoidossa
CN116332789A (zh) * 2023-03-10 2023-06-27 上海康鹏科技股份有限公司 一种4-氨基-2-氟苯甲酰胺的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2001278609B2 (en) 2000-08-21 2005-04-14 Astrazeneca Ab Quinazoline derivatives
ATE409185T1 (de) 2001-04-19 2008-10-15 Astrazeneca Ab Chinazolin derivate
RU2350618C2 (ru) * 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
GB0307333D0 (en) 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent

Also Published As

Publication number Publication date
AU2009200622A1 (en) 2009-03-12
US8304417B2 (en) 2012-11-06
US20090099196A1 (en) 2009-04-16
KR20080094847A (ko) 2008-10-24
JP2008524183A (ja) 2008-07-10
ZA200704532B (en) 2008-07-30
MX2007007210A (es) 2007-11-07
EP1871769B1 (en) 2017-02-22
NZ555468A (en) 2010-12-24
NO20072755L (no) 2007-07-02
JP5161584B2 (ja) 2013-03-13
EP1871769A2 (en) 2008-01-02
KR20110114727A (ko) 2011-10-19
CN101115744A (zh) 2008-01-30
AU2005315458B2 (en) 2009-03-12
KR20080094846A (ko) 2008-10-24
KR20080094849A (ko) 2008-10-24
WO2006064217A3 (en) 2006-12-21
WO2006064217A8 (en) 2007-07-05
CN101115744B (zh) 2012-02-01
IL183525A0 (en) 2007-09-20
BRPI0519085A2 (pt) 2008-12-23
WO2006064217A2 (en) 2006-06-22
ES2622480T3 (es) 2017-07-06
CA2590735A1 (en) 2006-06-22
KR20080094848A (ko) 2008-10-24
GB0427697D0 (en) 2005-01-19
JP2009143920A (ja) 2009-07-02
CA2590735C (en) 2009-11-10
CA2675642A1 (en) 2006-06-22
AU2005315458A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
EP1480650B1 (en) Novel crystalline forms of the anti-cancer compound zd1839
AU727013B2 (en) Heterocyclic compound and antitumor agent comprising the same as effective component
US10561646B2 (en) EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof
JP2009143920A (ja) 化学的方法
US20150133460A1 (en) Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
HK40034530B (en) 2-(2,4,5-substituted-anilino)pyrimidine compounds
HK40034530A (en) 2-(2,4,5-substituted-anilino)pyrimidine compounds
HK40034527B (en) 2-(2,4,5-substituted-anilino)pyrimidine compounds
HK40034527A (en) 2-(2,4,5-substituted-anilino)pyrimidine compounds
KR20210050530A (ko) 신규 아자트리시클릭 화합물의 염 형태 및 결정 형태 및 그의 용도
HK1070582B (en) Novel crystalline forms of the anti-cancer compound zd1839

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070712

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A107 Divisional application of patent
A201 Request for examination
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20080930

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080930

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20101119

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110729

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20101119

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20110829

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20110729

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20120911

Appeal identifier: 2011101006094

Request date: 20110829

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20110928

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20110928

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20110829

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20110119

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20080930

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20110829

Effective date: 20120911

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20120911

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20110829

Decision date: 20120911

Appeal identifier: 2011101006094